Modality
Peptide
MOA
CD3xCD20
Target
LAG-3
Pathway
mTOR
SchizophreniaMM
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
May 2018
→ Aug 2030
Phase 2Current
NCT04744256
2,942 pts·MM
2018-05→2028-11·Recruiting
NCT03415298
1,241 pts·Schizophrenia
2019-01→2030-08·Active
4,183 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-11-122.6y awayPh3 Readout· MM
2030-08-284.4y awayPh3 Readout· Schizophrenia
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Active
Catalysts
Ph3 Readout
2028-11-12 · 2.6y away
MM
Ph3 Readout
2030-08-28 · 4.4y away
Schizophrenia
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04744256 | Phase 2/3 | MM | Recruiting | 2942 | ACR20 |
| NCT03415298 | Phase 2/3 | Schizophrenia | Active | 1241 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |